Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
26 hedge funds and large institutions have $31.3M invested in Celgene Corporation Contingent Value Rights in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
6% less capital invested
Capital invested by funds: $33.3M → $31.3M (-$2.02M)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.44M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$463K |
| 3 |
PC
Pomelo Capital
New York
|
+$425K |
| 4 |
JGC
J. Goldman & Co
New York
|
+$308K |
| 5 |
FA
FCG Advisors
Chatham,
New Jersey
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$4.88M |
| 2 |
ACM
Ayer Capital Management
San Francisco,
California
|
-$2.68M |
| 3 |
O
OrbiMed
New York
|
-$1.07M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$53K |
| 5 |
JP Morgan Chase
New York
|
-$36.6K |
CELGZ Hedge Fund Activity: Q3 2013 in Review
26 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q3 2013, worth a combined $31.3M — down 6.1% from $33.3M a quarter earlier.
Fund positioning in CELGZ was balanced in Q3 2013: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.44M. The largest seller was Camber Capital Management, exiting entirely with an estimated $4.88M sold.
- 26 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $31.3M of Celgene Corporation Contingent Value Rights stock for Q3 2013, down 6.1% quarter-over-quarter.
- 4 funds opened new Celgene Corporation Contingent Value Rights positions in Q3 2013 and 4 closed out, a net change of 0 holders.
- The largest Celgene Corporation Contingent Value Rights buyer in Q3 2013 was Millennium Management, an estimated $2.44M added.
- The largest Celgene Corporation Contingent Value Rights seller in Q3 2013 was Camber Capital Management, an estimated $4.88M sold.
Based on aggregated 13F filings for Q3 2013.